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CHAPTER I 
 
INTRODUCTION 
 
Overview of Skin Cancer  
 Skin cancer is the most prevalent cancer in the United States, and in 2012 is 
estimated to be diagnosed in over 2 million new cases, resulting in roughly 12,000 
deaths.1 Because the classification and prognosis of skin cancer depends on the cells from 
which the cancer originates, two primary sub-groups have been delineated: melanoma 
and non-melanoma skin cancers. Accounting for fewer than 5% of skin cancer cases, 
melanoma skin cancers are responsible for a majority of related deaths. An estimated 
70,000+ melanoma cases will be diagnosed in the US during 2012 with incidence varying 
based on age, gender, and skin type. Alternatively, non-melanoma skin cancers are 
primarily accounted for by basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC). Originating in the deepest layer of the epidermis, roughly 80% of skin cancers are 
BCC, while the more aggressive SCC type account for most of the remaining 20%. Both 
of these cancers commonly appear on sun-exposed areas of the body like the face, ears, 
neck, back, and hands.2, 3 The risk of developing skin cancer is associated with 
Ultraviolet (UV) light exposure, presence of moles, fair skin, old age, previous skin 
cancer diagnosis, suppressed immunity, and smoking. Diagnosis of these malignancies is 
usually performed by visual inspection followed by biopsy to improve specificity, 
although other tools are becoming available. Accurate staging of the disease progression 
allows doctors to provide optimal treatment options to attain positive outcomes and 
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improve quality of life. Typical treatment options include surgery, local and systemic 
chemotherapy, immunotherapy and radiation therapy but the proper choice is both case 
and skin cancer-type dependent. 
 
Normal Skin: Form and Function 
 As the largest organ in the body, the skin is composed of an array of components 
and specialized cell types and is the fundamental barrier between the body and the 
environment. The skin plays a vital role in sensory reception, thermal regulation, 
immunological surveillance, fat and water storage, and protection against light, injury, 
and infection. To distinguish between both the structures and functions, the skin is 
divided into three main sublayers: the epidermis, dermis, and subcutis, which are 
depicted in Figure I.1. The skin is further divided into two descriptive groups based on 
inherent structures. The glabrous (non-hairy) skin, found on the palms of the hands and 
soles of the feet, has a uniquely patterned, grooved surface of alternating ridges that 
constitute a person’s dermatoglyphics (ie, fingerprints). This skin is characterized by a 
thick epidermis divided into well-defined layers and contains encapsulated sense organs 
in the dermis but no hair follicles or sebaceous glands. Hair-bearing (non-glabrous) skin 
has both hair follicles and sebaceous glands, but encapsulated sense organs are absent. 
Because of this change in composition, the hair acts as the sensory structure. Non-
glabrous skin composition is also highly variable between unique body sites.4 
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Figure I.1. Diagram of macroscopic view of skin.5 
 
 The epidermis is the outermost layer of skin tissue and has a layered composition. 
This avascular superficial layer is composed largely of keratinocytes, approximately 95% 
of the total cellular composition, that are formed by proliferation of the deeper layer of 
basal cells. Other native cell populations occur with differing frequency depending upon 
the level of the epidermis. At locations where hair follicles are present, the superficial 
epidermis extends deep into the skin forming a continuous pocket. This structure has a 
small segment of smooth muscle connected from the dermis to the follicle wall. Above 
the point of insertion, the sebaceous, or oil-producing, glands open into the follicle canal. 
The eccrine sweat glands of the epidermis open directly to the skin surface and are 
present in every region of the body.4 
 The epidermis is further divided into multiple layers. The outermost surface, the 
stratum corneum, is composed of large, flattened, dead polyhedral cells, or squamous 
cells, that are continuously shed as newer ones are formed. These cells have lost nuclei 
and cytoplasmic organelles, and the connective keratin filaments have aggregated into 
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cross-linked macrofibers. The more superficial the squamous cell, the more exaggerated 
the flattening. Only for the palmoplantar skin, a layer beneath the stratum corneum, 
called the stratum lucidum, is formed by three to five layers of dead flattened 
keratinocytes. The thickness and coloration of this region is controlled by the rate of 
mitosis of the epidermal cells and the presence of melanocytes in the tissue, respectively. 
The cells here are still nucleated and are often referred to as “transitional cells.” The next 
layer, the stratum granulosum is where the most highly differentiated viable 
keratinocytes of the epidermis are located. These squamous cells are called granule cells 
due to keratohyalin content, a protein that forms dense cytoplasmic granules that promote 
cell dehydration and keratin aggregation and cross-linking. The cellular cytoplasm also 
contain lamellated granules that discharge lipid content into the intracellular spaces 
affecting barrier function and intercellular cohesion.4 Descending further, the stratum 
spinosum comprises the first suprabasal layer of cells where adjacent cells are joined by 
adhesive desmosomes. The cells at this level are enlarged keratinocytes and contain 
typical cellular organelles, microfilaments, and melanosome-complexes, beginning as 
polyhedral-shaped cells that flatten during ascent to the skin surface. The deepest layer of 
cells associated with the epidermis is the stratum germinativum, a continuous layer of 
basal cells. These pluripotent cells are small, cuboidal cells with large nuclei, dense 
cytoplasm, and numerous ribosomes. They remain undifferentiated and reproduce 
regularly to maintain skin cell turnover.  
 Other structures that are of vital importance to the skin are melanocytes, Merkel 
cells and Langerhans cells. Melanocytes are the pigment-synthesizing cells and are 
generally confined to the basal layer with projections extending into the spinous layer 
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toward the skin surface. Keratinocytes are thought to phagocytize the processes of these 
uniformly distributed melanin producing cells and incorporate the melanin storing 
organelles, melanosomes, into caps within the cytoplasm positioned above the 
keratinocyte nucleus. This integration of melanosomes effectively distributes the skin 
pigment in a more homogeneous manner and affords better protection from incident 
light.6  
 A major nerve cell type located in the epidermis is the Merkel cell. These cells 
connect to an enlarged nerve terminal as a mechanical receptor for discrimination of 
light, sustained touch sensations. Merkel cells have a lobulated nucleus, characteristic 
granules in the cytoplasm, underlying nerve plate, and are associated with slow-adapting 
somatosensory nerve fibers. These have been found in all vertebrates, and are especially 
common in the stratum germinativum. An often missed and dangerous cancer type, the 
Merkel cell tumor, derives from this cell type. Merkel cell tumors have one of the lowest 
survival rates and diagnosis is often missed due to clinical appearance. 
 Another cellular population of the epidermis is the Langerhans cells. These cells 
are derived from precursor cells originating in the bone marrow and continually 
repopulate the epidermis.6 Similar to melanocytes, the Langerhans cells have a lobulated 
nucleus, pale cytoplasm, and extended dendritic processes among keratinocytes. The cell 
types are differentiated by the presence of Langerhans cell granules, which are disc-like 
vesicles. The function of these granules is still unknown, but they have been identified in 
many other species and cell types. The role of the Langerhans cells has also been 
debated, but is thought to participate in antigen processing for the skin’s immune system. 
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 Responsible for the separation of the epidermis from the dermis, the basement 
membrane, or dermal-epidermal junction, is a complex structure involving cells and 
extra-cellular matrix of both contiguous regions. This multi-layered barrier is connected 
by microfibrils and hemidesmosomes linking the layer of basal cells to the basal lamina 
and in turn to the reticular lamina. This network of anchoring fibrils continues deeper into 
the dermis, where it either terminates in a bush-like formation or loops back into the 
basement membrane and basal cell layer.6 Along with its role of mechanical support, this 
barrier serves as a size- and charge-selective filter, inhibiting anionic macromolecules 
and cells from deeper passage. 
 The dermis is the lower section of the skin located beneath the basement 
membrane. It is composed primarily of a supporting, extrafibrillar matrix or ground 
substance in which polysaccharides and proteins are interlinked to produce water storing 
macromolecules and impart bulk, density, and strength to the skin. Also present are high 
tensile strength collagen fiber bundles, the primary dermal constituent, and elastin fibers, 
the assembly, size, and density of which help to separate the region into layers involved 
in protection from disease and environmental attack. An array of fibroblasts, mast cells, 
and histiocytes comprise most of the remaining cells in the dermis.4  
 The superficial dermal layer is the papillary dermis and contains bundles of small-
diameter collagen fibrils. Including the invaginations in the region of the basement 
membrane, elastin fibers are present only in cross-linking or as a soluble coating around 
microfibril bundles. Cells are more abundant in the papillary dermis, fibroblasts have 
greater mitotic activity and there is a high density of blood vessels. At the deepest part of 
this layer is a horizontal plexus of blood vessels, forming a border with the deeper, 
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reticular dermis. From here, capillary loops extend superficially toward the epidermis to 
aid in thermoregulation and provide nutrients via diffusion.  
 The papillary dermis contains multiple sensory receptor types. Meissner’s 
corpuscles are fast-adapting sensory receptors for light, fluttering touch. Found deeper 
within the dermis are the Ruffini endings, which respond to deep, sustained mechanical 
pressure and stretch of the skin. The deepest layer of the dermis, the reticular dermis, is 
the outermost perfused layer of the skin. This region accounts for the bulk of the dermis, 
and includes large bundles of collagen fibrils and mature elastic fibers with a high 
proportion of elastin relative to the microfibrillar components.6 These elastic fibers are 
generally found between the collagen bundles.  
 Despite the lower cellular density of the reticular dermis, fibroblasts, mast cells, 
and macrophages are found in the interstitium between collagen bundles. The fibroblasts 
of the dermis are responsible for the synthesis, destruction, and remodeling of connective 
tissues. The shape of these cells is site-specific, but they are commonly located between 
bundles of collagen or in close association with individual collagen fibrils or elastic 
fibers. Nerve endings, the pacinian corpuscles, which are rapidly-adapting sensors of 
vibrations and deep pressure, are also present in the dermis. The macrophages found in 
the dermis range from early-development to fully-differentiated stages depending upon 
cellular surface markers. The late-stage macrophages are large with at least one nucleus 
and an abundance of lysosomes and phagocytic vacuoles. These cells are involved in the 
synthesis and secretion of hydrolytic enzymes, soluble factors affecting T-lymphocyte 
activity, prostaglandins, and interferon. Mast cells are specialized secretory cells that are 
common in the connective tissue matrix. Most common in the upper dermis, around 
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vessels, and around subcutaneous fat, Mast cells accumulate around sites of inflammation 
and wound repair.  
 Beneath the dermis is a layer known as the subcutis (hypodermis or subcutaneous 
layer). Together with cells in the dermis, the subcutis forms a network of collagen and fat 
cells. This layer also helps to conserve body heat and acts as a shock-absorbing layer to 
protect internal organs. The contents of the subcutis are highly varied, including loosely 
arranged elastin fibers, fibrous bands anchoring the skin to deep fascia, fat, blood vessels 
destined for the dermis, lymphatic vessels from the dermis, hair follicle roots, the free 
endings of nerves and Pacinian corpuscles, bursae overlaying the joints to facilitate 
movement, and fine, flat sheets of muscle. The subcutis is composed primarily of 
adipocytes, cells specialized for the accumulation and storage of fat. These adipocytes are 
grouped into lobules and separated by connective tissue.  
 
Aging of Skin 
 The aging process of skin has been clearly observed for many years primarily due 
to the ease of access to the tissue. Despite the highly individualized variability, the 
process is characterized by the overall physiological decline with increasing age. More 
recently, distinction has been made between inherent aging changes and age-related 
environmental changes, developmental changes, and age-related diseases. The most 
common and most important of these aging processes is “premature aging” induced by 
chronic sun exposure. This photo-aging is responsible for most of the clinically evident 
age-associated cutaneous change. 
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Figure I.2. Histological features of young, old, and photodamaged skin.6 
 
 Morphologically, the majority of aging change in sun-protected skin includes 
increased roughness, fine-wrinkling, laxity, and proliferative lesions. In sun-exposed 
skin, along with the aforementioned changes, the skin can experience elastosis (a pebbly, 
yellowed quality due to changes of elastic fibers), irregular hyperpigmentation and 
depigmentation, coarse wrinkling, and actinic keratosis. Histologically, the most striking 
change with aged human skin is the flattening of the dermal-epidermal junctions, as seen 
in Figure I.2, which causes a reduced transfer of nutrients, a smaller surface between the 
neighboring compartments, and a reduced resistance to shearing forces. For protected 
skin, the variability in epidermal thickness and keratinocytic size increases with age. The 
dermal microfibril bundles anchoring the basement membrane are reduced. Decreases in 
the number of enzymatically active melanocytes per unit surface area of the skin have 
been documented, reducing the body’s protection against UV light.6 Langerhans cells are 
thought to be reduced by 20 to 50% between early and late adulthood and may account 
for the decreased immunological response of aged skin. Dermal thickness has been 
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reported to decrease gradually with age, and a significant age-related loss of the dermal 
vascular bed and vertical capillary loops are believed to underlie many of the 
physiologically atrophic changes of aged skin. Loss of elastin fibers may result in the 
appearance of fine wrinkles and elastosis is believed to contribute to more pronounced 
wrinkling in photo-aged skin. Deep wrinkles associated with expression lines are thought 
to be caused by contractions of connective tissue within the subcutaneous fat.6  
 Changes in the color, density, and distribution of hair are widely recognized 
results of skin aging. Graying is caused by a progressive depletion of melanocytes from 
the hair bulb. Gray hairs may have remaining melanocytes with vacuoles, while the hair 
shafts contain fewer melanin granules than the normally pigmented hairs. The loss of 
melanocytes is thought to occur more quickly within the hair than the skin. The 
decreasing frequency of Meissner’s and Pacinian corpuscles, and increasing variation in 
size and distribution, of the nerve endings responsible for detection of light touch, lead to 
a decreased perception of low pressure mechanical stimuli.  
 Age-related decreases in the turnover of epidermal cells have been documented 
due to rates of desqumation, or shedding, of the stratum corneum. The replacement rate 
of surface cells decreases with age and causes the tissue to exhibit fewer of the traits of 
young, healthy skin. Many of the inter-related functions of the human skin that are 
affected with age can be found in Table I.1. The repair rate declines with age, especially 
in relation to wound closure, epidermal cell migration and mitosis, collagen deposition, 
and development of wound tensile strength.6 Because of the constant replication of cells 
in the basal layer of the epidermis, neoplasia is especially characteristic of aging skin. 
The prevalence of these growths is almost ubiquitous as explained by Soter. “One or 
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more benign proliferative growths are present in nearly every adult beyond the age of 65 
years, and most adults have dozens of lesions.” 6 A decrease in chemical clearing and the 
barrier function of the stratum corneum is reported for several substances as well as a 
decrease in sensory perception in old skin. The decreased immune function of the skin is 
presumed to impact the increased propensity for disorders such as skin cancer with 
increased age.  
 
Table I.1. Functions of Human Skin that decline with age Adapted from ref (6). 
Cell replacement Immune recognition 
Injury response Vascular responsiveness 
Barrier function Thermoregulation 
Chemical clearance Sweat production 
Sensory perception Sebum production 
Vitamin D production Mechanical protection 
 
 
Structure of Common Skin Lesions 
 As the exterior surface of the body, the skin affords opportunities for clinical and 
pathologic correlation due to its ease of access for physical examination and visual 
inspection. Due to the variety of potential lesions which denote significant and unique 
changes within the skin, it is important to have a working understanding of the common 
lesions associated with malignant and benign pathologies of melanoma and non-
melanoma lesions. A macule is a flat, distinct, colored area of skin that does not include a 
change in skin texture or thickness. It may result in any layer of the skin and any size or 
shape. The distinctive variation in color can result from epidermal hyperpigmentation 
(Figure I.3, i-A), dermal pigmentation (i-B), vascular dilation (i-C), or extravasated 
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erythrocytes (i-D). A papule is a small, solid, rounded bump rising from the skin that is 
usually less than 1 cm in diameter. The majority of these lesions are found above the 
plane of the skin and can result from metabolic deposits (Figure I.3, ii-A), cellular 
infiltrates in the dermis (ii-B), or localized hyperplasia of cellular elements in the 
epidermis or dermis (ii-C). Papules may open when scratched and become crusty and 
infected. The variation in color and shape of these lesions can be used clinically to 
differentiate several lesion types. Plaques are elevated, solid, superficial lesions more 
than 0.5 cm in diameter. A plaque tends to be flat over the whole surface and is often 
formed by confluent papules. A nodule is a palpable, solid, round or ellipsoidal lesion of 
varying size in either the dermis (Figure I.3, iv-A) of the epidermis (iv-B). A large nodule 
is a tumor, a term that can also apply to any mass, benign or malignant. A corresponding 
description of the nodule surface is also vital to differentiating lesion types. Drawings of 
each of these lesion structures can be seen in Figure I.3, to better understand the given 
explanation.  
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Figure I.3 (i-iv). Macroscopic structure of skin lesions for macule (i), papule (ii), plaque 
(iii), and nodule (iv). Letters correspond to specific structures mentioned in the text.6 
 
 
Risk Factors for Skin Cancer 
 There are many risk factors associated with the development of skin cancers, 
some having higher associated risks than others. The most indicative of these factors is 
exposure to UV radiation. This band of light has the potential to damage genes and alter 
cellular reproduction. People with higher accumulated lifetime exposure levels to these 
wavelengths of light are at an elevated risk. This light can come from natural sunlight, 
sunlamps or tanning beds. Fair skinned people, usually with blond or red hair and light-
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colored eyes, are at an increased risk, but people that have darker complexions or 
different skin types are also susceptible. The amount of UV radiation exposure is highly 
dependent upon the person’s lifestyle and geographic location, with increased exposures 
for latitudes nearer to the equator or high elevations. The UV band of the radiation 
spectrum can be divided into three categories: UVA, UVB, and UVC ranges. The UVA 
grouping, or long wave UV, has wavelengths that range from 315 to 400nm. These 
wavelengths can cause some damage to cellular DNA, reduce the cancer surveillance for 
skin immunity, and are primarily linked to long-term skin damage like wrinkles. The 
midrange UVB rays, from 280 to 315nm are considered to be the primary cause of skin 
cancer, as these rays can cause direct damage to cellular DNA, and are responsible for 
most sunburn cases.  The UVC grouping, from 100 to 280nm, do not penetrate the 
Earth’s atmosphere and therefore are not considered a common cause of skin cancer.  A 
subset of the population, including pilots and astronauts, are monitored for increased 
exposure to these UVC rays and are at an increased risk of developing skin cancer. These 
UV wavelengths are a primary cause of skin cancer due to the damage that they inflict on 
the DNA and genes that control cell growth. The subsequent uninhibited proliferation of 
cells can lead to the development of cancerous lesions. The amount of UV exposure 
depends not only on the intensity of the radiation but also on the duration of exposure and 
the level of protection afforded to the skin by clothing, sunscreen, or other layers. A 
noted misconception that having a sun-tan will protect even a fair-skinned person from 
skin cancer must be discredited.7  
 Frequent sunburns during childhood and high levels of exposure at a young age 
are also added risk factors. Fair skin is considered a factor increasing the risk of skin 
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cancer, as the protective melanin of less pigmented, fair skinned people is lower than in 
those with darker skin.3 The presence of scars, burns, or other long-term inflammatory 
conditions also predisposes people to the development of skin cancer. Increased exposure 
to certain chemicals, including arsenic, causes an increased risk. HPV infection and 
reduced immunity have been linked to increased risk of developing skin cancer. The 
presence of actinic keratosis or Bowen’s disease can develop into squamous cell 
carcinomas.3 Development of malignant melanoma occurs in up to 5% of total melanoma 
cases in people with congenital nevi and those who develop dysplastic nevi have an 
approximately 50% cumulative lifetime risk for melanoma.8, 9 While recurrence is 
strongly linked to lesion depth, the likelihood of developing a subsequent melanoma is 
also significantly increased compared to the rates of initial lesion development, and rates 
increase with positive family history for the pathology.5 Several other risks associated 
with malignant melanoma are listed in Table I.2. 
Table I.2. Risk factors for malignant melanoma (MM). Adapted from ref (10). 
Specific MM Risk Factors Relative Risk 
Melanocytic Nevi (MN)  
Atypical Mole Syndrome  
No personal or family history of MM 2-92 
Personal but no family history of MM 8-127 
(II) 1 family member with MM 33-444 
(III) ≥2 family members with MM 85-1269 
>50 common MN 2-64 
Congenital MN 17-21 
Phenotypic traits  
Freckles 3-20 
Fair complexion 2-18 
Blond hair 2-10 
Red hair 2-6 
Tendency to sunburn l-5 
Inability to tan 2-5 
Blue eyes 2-3 
Sun exposure  
Constant 2-5 
Intermittent 2-3 
Immunosuppression 2-8 
History of non-MM skin cancer 3-17 
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Skin Cancer types  
 Skin cells, like most cells in the body, reproduce rapidly early in life to allow the 
body to grow and develop. As a person reaches adulthood and proliferative rates 
decrease, skin cells normally grow and divide to form new cells needed only to maintain 
proper function. As the cells age and decrease in functionality, they die and are replaced 
by newer cells. Occasionally this process is altered and the body produces unneeded, new 
abnormal cells or old cells do not die off. Such cells accumulate to form a tumor which 
can be benign, pre-malignant, or malignant. Benign tumors are in general, rarely life 
threatening, can be removed with little chance of recurrence, and seldom do constituent 
cells spread to neighboring tissues. For cancerous or malignant growths, removal can 
often occur, but regrowth is possible. These malignant growths are more serious and may 
be life threatening. The cells of these growths can invade and damage nearby tissues and 
organs or enter the blood stream or lymphatic organs through a process known as 
metastasis. Depending on the type and location of the primary cancer (site of the original 
tumor), the spread of cancer can have a wide range of metastatic targets.  
 As mentioned above, the cancers that form in human skin are divided into two 
major subgroups: cancers originating in melanocytes and those that do not. This second, 
broad and somewhat vague classification is mainly composed of cancers called 
keratinocytic carcinomas as the cells share common features with the keratinocytes of the 
epidermis. Both of these malignant subgroups have associated benign lesions that must 
be well characterized for proper discrimination between the serious cases of cancer and 
the less worrisome benign or pre-malignant growths. First the cases of non-melanoma 
type cancers will be handled. Within this subsection, basal and squamous cell carcinomas 
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are the most common forms of skin cancer, generally appearing on the head, face, neck, 
hands and arms. 
 
Non-melanocytic Skin Cancer 
 Basal cell carcinoma (BCC) is so named because it is thought to originate from 
freely differentiating cells in the basal layer of the epidermis. The cells present in these 
tumors also have many features in common with the cells of the exterior skin layer. 
Accounting for almost 80% skin cancers and as the most common malignancy in white 
people, these cancers are thought to result primarily from increased levels of exposure to 
the damaging rays of the sun.3 These lesions tend to grow slowly, are generally 
asymptomatic aside from crusting, and rarely spread to nearby lymph tissue or distant 
sites in the body. If left untreated, these lesions can grow deep in the tissue, through the 
basement membrane and even into deeper structures like bones. The incidence of this 
cancer shows high geographical variation, and in North America, there is a 30% lifetime 
risk of acquiring this malignancy.  
 While increased exposure to UV radiation is a major causative factor, this alone 
does not seem sufficient to account for the wide variation in appearances of the lesions, 
nor for the occurrence in some people and not others.11 Personal susceptibility depends 
greatly on interactions between intensity and duration of exposure to UV radiation and 
genetic makeup. Lesions that are present in clusters or develop on the trunk, are each 
associated with distinct predispositions. Those with basal cell carcinomas of the trunk 
generally have more total BCC lesions, are younger, and develop more clusters.11 The 
appearance of these lesions also varies markedly depending upon location on the body. 
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Roughly 80% of these lesions appear on the head or neck. Early BCCs are commonly 
small, translucent or pearly, with raised areas through which dilated vessels may show. 
The classic presentation is a hardened edge and ulcerative center. Other patterns include 
nodular or cystic, superficial, morphea form and pigmented. Superficial BCCs generally 
occur on the trunk, are often flat and particularly slow growing, potentially mimicking 
psoriasis, eczema or Bowen’s disease. The most important clinical subtype, accounting 
for 5% of BCCs, is the morphea form BCC due to its aggressive nature, late presentation, 
and difficulty in both diagnosis and complete excision. Patients with this lesion have an 
increased likelihood to develop another BCC or an SCC and the lesions can commonly be 
misdiagnosed as scars, SCCs, malignant melanomas, melanocytic nevi, or Bowen’s 
disease among others. 
 Squamous cell carcinoma (SCC) accounts for two in every ten cases of skin 
cancer and commonly appears on sun-exposed (actinically damaged) areas of the body. 
These erythematous lesions have varying degrees of scaling and crusting.6 These lesions 
develop on sun-protected areas as well as scars or skin ulcers, sometimes beginning as 
actinic keratosis (described below). The lesions that form on sun-exposed areas are most 
commonly found on body parts that receive the highest levels of irradiation including the 
top of the nose, the forehead, and the lower lip. This subgroup of SCCs is similar in 
behavior to BCCs, with the exception of lip SCCs, which are more aggressive. When 
SCCs occur in sun protected regions, the lesions tend to be more aggressive, more likely 
to invade nearby fatty and lymph tissues or metastasize. The SCCs commonly occur as 
multi-nodular tumors with surface loss due to abnormal epidermal cells or poorly defined 
nodules or plaques with crusting or eroded surfaces. Often these tumors are red and 
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elevated and can also have a cutaneous horn.6 The cells at the base of these tumors show 
poor differentiation and consist of various sized masses of epithelial cells with 
pleomorphic nuclei, cellular keratinization, and atypical mitotic figures.12 Difficulty in 
diagnosing these lesions often arises from an inability to determine the extent of 
superficial invasiveness of the tumor. 
 Keratoacanthomas are growths that are found on sun-exposed skin that usually 
initialize with rapid growth over a 2- to 3-week period without a pre-existing lesion. 
These solitary lesions appear as dome-shaped, red, smooth nodules, 1 to 3 cm in 
diameter, with a central keratinous plug that is lost, leaving a crater.13 After a period of 
stasis, these lesions generally regress without treatment, often leaving scar tissue.12 
Because of the rapid and unpredictable growth of these eventually benign lesions, many 
specialists consider these as a subtype of SCC. Other types of non-melanoma skin 
cancers are derived from the other cell types found within the skin and include Merkel 
cell carcinoma, Kaposi sarcoma, cutaneous lymphoma, skin adnexal tumors and various 
other sarcomas. Because these types together account for less than 1% of skin cancers, 
they will not be covered further. 
 Pre-cancerous or pre-invasive skin conditions may be either early stages of skin 
cancer or may develop into skin cancer. Two such pre-cancers are of particular interest: 
actinic keratosis and Bowen’s Disease. Actinic keratosis (AK) is caused by excess 
exposure to the sun and usually results in atypical epidermal cells in small, rough spots 
that may be pink-red or flesh-toned.3 These lesions often appear in groups but have 
poorly-defined edges and can coalesce to form large patches. Most common in 
individuals with fair complexion, if untreated, these intraepidermal malignancies can 
20 
 
become SCCs.5 The chromosomal abnormalities expressed in the presence of proteins 
(p53) and growth factors (Ki-67) show that this is a stage of neoplastic transformation. 
The rate of progression from AK to SCC is likely 0.1 to 10% over a lifetime.14 The actual 
risk of subsequent lesion metastasis is between 2 and 6%.15 Bowen’s Disease (BD) or 
squamous cell carcinoma in situ presents as sharply marginated, erythematous, scaly or 
verrucous (wart-like) plaques with variable pigmentation.12 These lesions are regarded as 
the earliest form of SCC, where the cells are still entirely located in the epidermis prior to 
dermal invasion.3 Bowen’s Disease is often similar in appearance to psoriasis with 
hyperkeratosis replaced with crusting, but the two lesions are sometimes 
indistinguishable.13 Often a result of overexposure to UV radiation, BD may also be 
caused by HPV infection or exposure to inorganic arsenic.12 
 Due to the high variation observed in numerous different benign lesions of the 
epidermis, most of these cases will be ignored to focus on the most common lesion types. 
For further information regarding epidermal lesions and associated clinical features, 
pathologic findings, and differential diagnoses, please consider reference (12) listed 
below. Aside from the conditions covered previously, seborrheic keratosis (SK) and 
epidermal cysts comprise the majority of clinically observed non-melanocytic lesions.12 
Epidermal cysts are smooth, dome-shaped, freely-movable subcutaneous swellings. They 
are commonly walled-off cavities that are filled with keratin, derived from the hair 
follicle unit, and found on the face, neck or trunk.13 These usually solitary lesions have 
been reported to rarely cause SCC, BCC, or BD.12 Seborrheic keratoses are extremely 
common lesions that mimic both pre-malignant and malignant lesions and occasionally 
confused with pre-malignant or malignant melanocytic lesions. These common benign 
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keratotic skin growths increase in prevalence with age and are usually rough-surfaced 
papules, nodules, or plaques.12 Because of the clinical variation presented, it is necessary 
for clinicians to understand the significant differences between these benign lesions and 
tumors. These pre-malignant lesions that can appear as highly pigmented tumors or 
varying size are commonly confused with the second major classification of cancerous 
tumors, malignant melanomas, which will now be considered in detail. 
 
Malignant Melanoma 
 Melanomas are malignant lesions that begin formation within the melanocytes 
and, therefore, are most commonly hyperpigmented lesions. These lesions are widely 
considered to be the most serious type of skin cancer, originating in the epidermis but are 
much less common than SCC and BCC. Melanomas account for 65% of all skin related 
cancer mortalities, mainly due to the likelihood of metastasis when not detected early 
during development.16 The presence of melanoma cells spreading to nearby lymph nodes 
may signify that cancer cells have reached to vital organs including the liver, lungs, or 
brain.5 When detected at an early stage, like non-melanocytic cancers, melanoma can be 
treated with a high cure rate. Melanoma lesions can appear anywhere on the skin but 
often present on the trunks of males and the lower legs of females, or other sun exposed 
areas, especially the head and neck.2 Because of the protection against harmful radiation 
that melanin affords, people with dark pigmentation are less likely to develop melanoma, 
but when it does occur, it is commonly found beneath fingernails or on the palms or soles 
of the feet. Unlike other cancers, melanomas are prevalent in young people as well, with 
40% of cases occurring in people under age 50. The highest levels of incidence are still 
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found in the near age 55 range.17 For patients diagnosed at age 75 or above, lesions are 
deeper and have higher mortality. These lesions can arise either directly from 
melanocytic growth or from pre-existing melanocytic nevi (moles). The most important 
prognostic factor for all melanoma lesions is the depth of invasion. Often because of the 
heterogeneity of clinical appearance, the melanoma can escape detection or be confused 
with other cutaneous lesions. Of greatest importance in distinguishing these lesions is 
consideration of a change in some aspect of the lesion, such as size, shape, color, or 
symptoms. Keeping the overall time-course of a lesion in mind, new or changing 
pigmented lesions in adults should be viewed with suspicion.13 People that have had a 
melanoma in the past are also at increased risk of developing subsequent melanoma 
lesions in their lifetime. 
 As with the non-melanoma cancers, melanomas have associated benign tumors 
that must be well characterized for successful distinction during clinical diagnosis. 
Different types of these benign lesions develop due to proliferation of melanocytes and 
present as persisting macules, papules, plaques, and nodules. Such lesions can occur as 
the result of increases in melanin or melanocyte frequency within the cutaneous tissue. 
The benign lesions commonly associated with malignant melanoma are various nevi, 
including acquired, dysplastic, and congenital forms. These moles result from 
aggregation of melanocytes either at the epidermal/dermal junction, within the dermis, or 
both. As the name implies, congenital nevi are present either at birth or develop within 
the first two years of life, and commonly have 1 of 4 distinct histological types. They 
may have the distinct characteristics of nevus cells present in deep dermis (between 
collagen bundles) and subcutis, and infiltrate vessel and nerve walls of the deep dermis.8 
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Congenital nevi may be macular but often exhibit varied pigmentation and thickness, 
sometimes including the presence of hair. Another common presentation of nevi appears 
in the center of a de-pigmented zone, at which point they are classified as halo nevi. This 
condition is fairly common in young adults, characterized by the lack of melanin in the 
region surrounding a nevus, and is commonly caused as an immune response to a nevus. 
Depending upon the lesion, both the central lesion and halo can fade over time.18 
Acquired nevi are usually flat and small plaque, or dome-shaped papules or nodules. 
These usually increase in number until the third decade of life then decrease. Most 
commonly, these are relatively uniform and symmetrical in shape and color, but both of 
these traits can alter over time. Acquired nevi are common and alone do not pose a health 
risk. However, as the total number of acquired nevi increases, especially above 100, so 
does the risk of malignant melanoma. Dysplastic nevi have increased malignant potential, 
commonly pale-, red-, or tan-colored, appear early in life and in higher numbers than 
average. These are often larger in size, varied in color, shape, and contour, and are passed 
by autosomal dominant inheritance. Clinical features of note for dysplastic nevi can be 
found in Table I.3. The importance of the presence of a solitary dysplastic nevus, which 
is present in 5-10% of the US population, is unclear, but people with higher lesion counts 
have an increased risk of developing melanoma.19  
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Table I.3. Clinical Characteristics of Patients with Classic Dysplastic Nevi.20 
Feature Clinical finding 
General clinical 
characteristics 
 
No. of nevocytic nevi Often many (>75) including non-DN* 
Uniformity of dysplastic 
nevi 
Heterogeneous (neighbors differ) 
Clinical characteristics 
of dysplastic nevi 
 
Size Vary, but at least some over 7 mm diameter 
Color Variegate; multiple shades of tans, browns, 
black, red 
Elevation May be raised centrally 
Perimeter Fades imperceptibly into surrounding skin 
Shoulder Peripheral macular tan zone 
Surface  Often mammillated (pebbly), cobblestoned 
Location Usually trunk > limbs > face 
Change Relatively stable once fully developed 
Sun-exposed sites DN greater numbers on sun exposed versus 
non-sun-exposed sites 
Non-sun-exposed sites DN greater numbers than non-DN* 
Hypertrichosis Absent 
Symptoms None 
Erosion/ulceration Absent 
 
 
Current Diagnostic Methods 
 Early diagnosis for all classes of skin lesions requires regularly performed self-
examination of the entire body. Because of the variability discussed above between lesion 
types, it is often most important for each person to know the groupings and patterns of 
lesion formation on their body and to be able to recognize new or expanding lesions. 
Specifically for potential melanoma lesions, the basic rule “ABCDE” can be helpful for 
evaluation of suspicious lesions: asymmetry, border, color, diameter, and evolution. 
Suspicious lesions will often appear asymmetric with a ragged or irregular border, exhibit 
variation in color across the lesion, have a large diameter of more than 5mm and the 
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appearance will alter over time, as demonstrated in Figure I.4. This rule helps during 
classification a suspicious lesion based on some of the criteria used to distinguish 
dangerous cancers. Once suspicious lesions are found, it is important to bring them to the 
attention of a health care professional for accurate diagnosis. The next step towards a 
diagnosis will include a medical history and physical examination of the lesions in 
question. Some dermatologists currently employ a technique called dermoscopy on 
patients to improve discrimination between lesion classes prior to an invasive biopsy. 
This technique relies on epiluminescence microscopy as a noninvasive method that 
allows the in vivo evaluation of colors and microstructures of the epidermis, the dermal-
epidermal junction, and the papillary dermis, which are not visible to the naked eye. In 
the hands of an experienced clinician, some distinctions can be made between the 
melanocytic versus non-melanocytic and malignant versus benign nature of some 
lesions.21  Early and accurate diagnosis of suspicious lesions is vital for medical care 
providers to mitigate excess stress for patients and dictates the treatment methods. In a 
study published by Stern et al, it was demonstrated that 49% of cases of seborrheic 
keratosis had a correct preoperative diagnosis.22 While this is not pivotal for SK, which 
does not generally mandate lesion removal, such inaccuracy could be devastating for 
more severe lesions.  
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Figure I.4. The ABCD features of early melanoma. A) Asymmetry of early melanoma; 
B) Border irregularity of early melanoma; C) Color variegation of early melanoma; D) 
Diameter of early melanoma of approximately 2mm.23 
 
 If a lesion is considered suspicious after visual examination, a biopsy will be 
taken as the gold standard for proper diagnosis. This can be a shave biopsy, removing the 
top layers of epidermis and dermis with a surgical blade, a punch biopsy, to take a deeper 
sample through the epidermis, dermis and subcutis, or an incisional or excisional biopsy 
technique, corresponding to partial or complete removal of the lesion plus some tissue 
from deeper layers. For each of these options, the samples will be examined via 
microscope by a trained pathologist to determine status of the sample. For suspicious 
lymph nodes, special lymph biopsy techniques can be used to diagnose the potential 
spread of cancer as well, including fine needle aspiration biopsy, surgical lymph node 
biopsy, and sentinel lymph node mapping and biopsy. Cases of later stage melanoma 
with expected or possible metastases may employ imaging tests to assess the spread of 
cancer to lymph nodes or other organs. Common detection methods used for these 
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analyses include chest x-ray, computed tomography (CT), magnetic resonance imaging 
(MRI), positron emission tomography (PET), and bone scans, as listed in  Table I.4.2  
 
Table I.4. Comparison of Emerging Technologies in Melanoma Diagnosis.16 
Technology Sensitivity Specificity Advantages Disadvantages 
MoleMax N/A N/A Two camera system; no oil 
immersion required; transparent 
overlay for follow up; total body 
photography 
No computer diagnostic analysis 
MelaFind 95-100% 70-85% Multispectral sequence of images 
created in <3 seconds; Handheld 
scanner 
- 
Spectrophotometric 
Intracutaneous 
analysis 
83-96% 80-87% Diagnosis of lesions as small as 
2 mm in diameter; observes skin 
structure, vascular composition 
and reticular pigment networks; 
handheld scanner 
- 
SolarScan 91% 68% Empirical database for 
comparison; session, and image-
level accuracy calibration; 
recorded on graphic map of body 
Requires oil immersion 
Confocal scanning 
laser microscopy 
(CSLM) 
98% 98% Histopathological evaluation at 
bedside with similar criteria; 
longer wavelengths can measure 
into papillary dermis; fiber-optic 
imaging allows for flexible 
handheld devices 
Poor resolution of chromatin 
patterns, nuclear contours and 
nucleoli; can only assess to depth 
of 300 µm; melanomas without in 
situ component will likely escape 
detection 
Optical coherence 
tomography (OCT) 
N/A N/A High resolution cross-sectional 
images resembling 
histopathological section of skin; 
higher resolution than ultrasound 
and greater detection depth than 
CSLM 
Photons are scattered more than 
once, which can lead to image 
artifacts; ointment or glycerol may 
be needed to reduce scattering and 
increase detection depth; 
observation of architectural 
changes and not single cells 
Ultrasound 
technology 
99% 99% Cost effective; information about 
inflammatory processes of skin 
in relation to nerves and vessels 
Tumor thickness may be 
overestimated because of 
underlying inflammatory infiltrate; 
melanoma metastasis cannot be 
separated from that of another 
tumor; images can be difficult to 
interpret 
Tape stripping 
mRNA 
69% 75% Rapid and easy to perform; 
painless; practical for any skin 
surface; can retest same lesion 
Results based upon small data set; 
delay in getting test results; need 
larger gene expression profiles for 
comparison; must send samples out 
for analysis (added cost) 
Electrical 
bioimpedance 
92-100% 67-80% Complete examination lasts 7 
minutes 
Electrical impedance properties of 
human skin vary significantly with 
the body location, age, gender, and 
season 
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A novel detection method that is now commercially available and is under 
continued investigation for diagnosis of melanoma is MelaFind©. This small device uses 
multiple wavelengths of light to probe the tissue structures at multiple depths to develop a 
diagnosis based on quantified cellular assembly. While dermoscopy is the current 
standard of care, other new technologies to improve and aid diagnostic outcomes 
including the MoleMaxII© imager and SolarScan© use the same diagnostic algorithms, 
helping the physician to focus on particular aspects of a lesion before characterization. 
These new imaging-based technologies rely on high-resolution images of the lesions to 
help direct diagnosis within the clinical setting and are still under investigation 
worldwide, but they are generating databases for future diagnoses and are demonstrating 
the potential for improved diagnostic adjuncts for lesion differentiation.22  
 
Current Treatment Methods 
 Treatment options for skin cancer depend upon stage, location, and classification 
of the disease, but most techniques are consistent across the disease type. The most 
common of these treatments include surgery, chemotherapy, immunotherapy, and 
radiation therapy. For most cases of skin cancer, surgical excision is the main form of 
treatment and is usually successful in curing early stage melanomas and most SCC and 
BCC cases. Thin lesions, including melanomas, can be cured using simple excision, 
which is similar to an excisional biopsy with the removal of a larger margin of healthy 
tissue to prevent local recurrence. The extent of this border depends upon thickness of 
each removed lesion. For small BCC and SCC, curettage and electrodesiccation are used 
to remove the cancer via scraping and coagulation of local tissue with electrode for 
repeated treatments. Microscopically-controlled or Mohs surgery is also common in SCC 
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and BCC. This process requires a surgeon to remove a thin layer of skin that the tumor 
may have invaded and to examine the whole layer under magnification for cancerous 
cells. If cancer is detected, the process is repeated until a layer is found lacking the 
presence of malignancy. This treatment is slow but tends to preserve normal skin near the 
lesion. There is some debate as to whether this treatment option should be employed for 
melanoma, requiring special tissue stains and no frozen sections, with concerns about 
recurrence.2 Often, a sentinel node biopsy is performed by an oncological surgeon prior 
to a definitive procedure, limiting the need for a Mohs procedure. 
 More extreme cases of melanoma on the extremities or digits can require partial 
or total amputation to treat the cancer, but this is rare. For both SCC and melanoma, 
when the tumor has spread to nearby lymph nodes, the lymph tissue near the lesion can 
be dissected after a confirmed biopsy, but such procedures are rare due to associated 
complications. Early basal and squamous cell carcinomas are also commonly treated 
using other local methods including cryosurgery, photodynamic therapy (PDT), or local 
topical chemotherapy. Cryosurgery and curettage are common treatments for the pre-
cancerous AK, of which cryosurgery is considered the standard of care.24 PDT is less 
common for treatment of these cases due to the associated risk of damage caused by the 
photosensitizers for lesion targeting.25 For metastatic melanoma cases, surgery is unlikely 
to cure the disease but is occasionally used to help control the extent of spread. 
 Systemic chemotherapy may be used to treat SCC and melanoma cases through 
the action of either injected or ingested drugs. Many such drugs are employed for each 
type of cancer and development of more efficacious alternatives is ongoing. Some of the 
recent and most promising options for melanoma chemotherapy treatment include 
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CTLA4 inhibitors (vemurafenib) to activate the immune response and BRAF inhibitors 
(ipilimumab) for the V600E BRAF mutation following mutation analysis. Attempts have 
been made to use cocktails of these drugs, as well as to localize the administration of the 
drugs to improve treatment outcomes. Studies suggest that combination chemotherapy is 
no more effective in treatment of metastatic melanoma than single-agent chemotherapy at 
increasing overall survival rates and is associated with more adverse effects than the 
single-agent counterpart.26 Immunological treatment options involve the drug-induced 
activation of intrinsic immune responses to recognize and attack cancerous cells. These 
methods have shown effect in both non-melanoma (AK and BCC) and melanoma 
treatments. Examples include Interferon injection to boost immune response or 
application of Imiquimod cream, 5FU cream, or ingenol mebutate  to stimulate immune 
response to cancer cells. Melanoma vaccines are under investigation in clinical trials, and 
BCC vaccine is used to stimulate the immune system by injecting a relative of the 
tuberculosis causing germ. Cytokines are proteins that boost the immune response upon 
injection and have been used for advanced stages of melanoma.2 A new drug inhibiting 
the hedgehog signaling pathway (vismodegib) has promise for improved BCC treatment. 
 Radiation therapies have also been explored as avenues for the treatment of skin 
cancers. Lesions are targeted and treated using high-energy rays (x-rays) or particles 
(photons, electrons, or protons). The intense radiation treatment is common for large 
lesions or for patients that cannot tolerate surgery. This radiation therapy can potentially 
cure small, non-melanoma cancers, treat advanced stages of cancer or recurrent 
melanoma or metastases. Each of these treatments is associated with risks and side-
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effects, so clinical options are determined with the help of a physician or health care 
professional depending upon the lesion status. 
 
Optical spectroscopy  
 There are several drawbacks to current diagnostic methods for skin cancer. Most 
screening and diagnostic techniques rely on initial visual inspection, which can lead to 
false positives, and tissue biopsy, which is a subjective, slow, and relatively costly 
procedure prone to sampling error. Biopsy can also be painful and yields information 
only about a single location. Thus, there is a need for an accurate, real-time, non-invasive 
diagnostic tool. Optical techniques are particularly appealing for skin diagnosis because 
of the ease of access to the tissue of interest, the clinically relevant measurement times, 
and their potential for in vivo applications. Numerous optical spectroscopy techniques 
have been investigated as a potential solution to this diagnostic dilemma, particularly 
fluorescence, elastic scattering, and Raman spectroscopy.  
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Figure I.5. Jablonski diagram illustrating principles of common optical spectroscopic 
phenomena. Si denotes electronic energy state and νi refers to vibrational energy level.  
The horizontal dashed line represents a virtual excited state. 
 
Fluorescence and diffuse reflectance  
 As shown in Figure I.5, fluorescence occurs when a photon is absorbed, heat is 
dissipated through internal conversion, and energy is subsequently re-released as a 
photon of lower energy. In tissue, autofluorescence signals from certain compounds like 
NADH, collagen, flavins, and porphyrins provide information about the metabolic or 
biochemical status of the tissue, and can be used to distinguish healthy and diseased 
states. Elastic, or Rayleigh, scattering is characterized by the change in path of an 
incident photon without losing or gaining any energy. This technique, also known as 
diffuse reflectance, provides morphological information about the tissue, such as number 
and size of scattering nuclei. Since these two techniques both have strong signals and 
provide complementary information, they are often combined to maximize diagnostic 
potential. Fluorescence and diffuse reflectance have been applied to cancer detection in 
33 
 
many areas of the body, including cervix 27-29, skin 30, 31, breast 32-34, and brain. 35, 36 The 
success these techniques have experienced in certain areas has been limited by their 
ability to distinguish among many different classes of disease due to the detected broad 
peaks.37 This is especially true in the skin, where pigmentation and external chemicals 
can severely limit the penetration depth of the potentially dangerous UV excitation 
source. 
 
Raman spectroscopy  
 Raman spectroscopy employs Raman, or inelastic, scattering. This occurs when 
an incident photon causes a scattering molecule to enter a virtual excited state and return 
to a ground state, which can be higher or lower than the original, through the emission of 
another photon, as seen on the right side of Figure I.5. Raman Stokes scattering occurs 
when the scattered photon has less energy than the incident photon, while Raman Anti-
Stokes scattering occurs when the scattered photon has more energy than the incident 
photon. In contrast to fluorescence, which involves transitions between electronic energy 
levels, Raman scattering utilizes small transitions between vibrational energy levels. As 
this signal is less intense, a powerful laser source and sensitive detector is needed, as well 
as the removal of the much stronger fluorescence signal. A Raman spectrum is a plot of 
scattered light intensity versus the Raman shift of the scattered photon, resulting in 
sample information that is independent of excitation wavelength. The Raman shift is 
expressed in units of wavenumber, which is the reciprocal of the wavelength, and thus 
proportional to frequency. Spectra consist of a series of peaks, each of which represents a 
different vibrational mode of the chemical bonds or functional groups within a scattering 
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molecule. These peaks are narrow and highly specific to a particular bond, giving each 
molecule a unique spectrum from about 700 to 2000 cm
-1
, or “fingerprint.” Many 
biological molecules have distinguishable spectra, which can be used to determine the 
gross biochemical composition of a tissue from its Raman spectrum. One particularly 
relevant biochemical change previously discussed for cancer cells is an increase in the 
nucleic acid content concomitant with increased proliferation and genetic instability. This 
change, among others, can be detected with Raman spectroscopy.38, 39 
 Raman spectroscopy has historically been used in analytical chemistry to 
determine chemical structures or the presence of certain molecules, but has recently 
become a popular tool for studying tissue. This is largely due to the non-invasive and 
non-destructive nature of optical spectroscopic techniques, as well as the breadth of 
information that can be obtained from a single Raman spectrum. The majority of studies 
have been in vitro, attempting to distinguish normal from cancerous tissue in areas like 
cervix 40-43, breast 44-46, bladder and prostate 44, 47, lung 48, GI tract 44, 49, and the skin. 
Many have written of the challenges of bringing Raman to in vivo applications 50-52, but it 
has been successfully applied to cervix 53-56,
 
GI tract 57-59, and breast 60. Human skin, 
because of its ease of access, has seen a great deal of study by Raman spectroscopy. 
Earlier in vitro studies used mostly Fourier Transform (FT)-Raman to examine skin 
structure 61-67
 
and to attempt to distinguish normal from cancerous tissues.68, 69 Due to the 
required integration times and instrumentation constraints, FT-Raman is not applicable 
for a clinical setting. An in vitro study used traditional Raman spectroscopy to distinguish 
BCC from normal tissue by producing two-dimensional Raman images.66
 
Many in vivo 
studies have been performed as well, especially examining carotenoid content of the 
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skin70-74, which is thought to play a role in defense against malignancy. Considering only 
the numerous reports of using fiber optic probe-based in vivo studies, many have 
investigated various structural and biochemical aspects of the skin75-79, and several 
groups have used Raman spectra in combination with fluorescence or advanced 
multivariate statistical techniques to improve performance of discrimination between 
normal and cancerous tissues.80-83 Recent reports have focused on clinical 
implementation of conventional fiber optic probe based Raman spectroscopy and 
reported  distinctive spectra obtained from a large patient population.78, 83 Despite these 
findings, practical concerns and independent validation are required before this technique 
can be widely implemented as a clinical tool. 
 As a stratified and heterogeneous tissue that is physiologically and optically 
complex, dermatological applications may have need of depth-resolved data. To this end, 
several groups have applied confocal Raman spectroscopy or Raman microspectroscopy 
to gather data from only a thin layer of the skin at a time. In vivo, these techniques have 
been applied to monitoring treatments 84, 85, determining molecular concentration profiles 
61, 70, 86-91, and to discriminating between normal skin and BCC.92-95 In our lab, previous 
studies have combined Raman techniques with other imaging modalities like optical 
coherence tomography and confocal imaging96, 97, and used confocal Raman spectroscopy 
to distinguish among SCC, BCC, and non-normal benign tissues, like scar, when 
comparing the spectra to their respective normal spectra.98, 99 Despite the numerous 
studies of skin with these and many other techniques, the previously mentioned changes 
to the tissue, the broad array of potential lesions, and its size have made fully 
characterizing and diagnosing these afflictions difficult. 
36 
 
CHAPTER II 
 
ASSESSING VARIABILITY OF SKIN RAMAN SPECTRA 
 
Introduction 
 Several research groups have reported using Raman spectroscopy (RS) to detect 
subtle changes in the skin related to wound healing, disease, natural moisturizing factor 
levels, protective antioxidants such as carotenoids β-carotene and lycopene, and 
cosmetics. The non-destructive nature of RS is ideal as an analytical or clinical tool for 
non-invasively monitoring the skin for changes associated with damage, disease, or 
treatment. Raman spectroscopy is sensitive to the biochemical composition of a sample 
without exogenous dyes, contrast agents, or extensive sample preparation. Because the 
underlying optical phenomenon is weak, the technology for in vivo skin measurement has 
only become available in the last 2 decades. Since the initial reports of human skin 
spectra in 1992, technological development and technique refinement have enabled in 
vivo Raman measurement. Studies have shown that spectra can be collected, corrected for 
undesirable signal components, and processed to rapidly provide feedback for users.79, 100, 
101 Previous reports have identified criteria required for adopting a novel biomedical 
diagnostic technique. In medical applications, many of these requirements are satisfied by 
RS for in vivo use: sensitivity to changes in tissue, application to in vivo studies, and 
novelty of information obtained non-invasively.51, 52 However, standard Raman spectral 
databases are not available for tissue, limiting RS’s role in influencing clinical decisions 
and patient prognoses. Both research lab and private industry studies using RS to 
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diagnose disease or understand tissue are becoming more common, but the RS 
community lacks a thorough understanding of the comparability of measurements made 
across multiple systems, tissue locations, and collection times. 
 Raman spectroscopy has been applied to the skin to study numerous changes. 
Skin is a complex and turbid tissue, with a layered structure, multiple functions, and 
inhomogeneous composition that can vary widely between patients and among various 
sites on a single patient. Several groups have demonstrated the feasibility of using RS to 
differentiate between skin malignancies and healthy tissues in vitro.66, 69, 79 These studies 
also showed that different spectra correlate with specific skin disease types. Tissue 
components and structural conformations for several biomolecules related to skin 
function, including proteins, lipids, and carotenoids, have been determined based on 
Raman vibrations. These results have yielded new information about skin aging and 
structural properties that may differentiate disease types from normal tissues.64, 70, 73 The 
healing of acute and chronic skin wounds has been monitored non-invasively with RS to 
provide new information on the biochemistry and progression of this complex process.102-
104 Benign conditions like psoriasis and atopic dermatitis, hydration differences, and the 
effect of topical treatments have also been studied using RS.77, 105-108 
 Current reports suggest that RS can be translated into the clinical setting with 
portable systems and fiber optic probes. However, as a clinical tool, RS measurements 
must be repeatable and free of confounding factors introduced by the system operator. 
With the probe-tissue interface of these systems, both contact pressure and probe angle 
can change, so the effects of user-induced variability must be understood and controlled. 
Other research groups have reported the effects of probe contact pressure on 
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measurements of diffuse optical spectroscopy and fluorescence spectroscopy in soft 
tissues.109-112 Shim et al. reported no specific major spectral artifacts from contact 
pressure and probe angle on in vivo RS measurements during clinical gastrointestinal 
endoscopy.59 To ensure that user perception of contact pressure and probe angle will not 
confound spectral measurements of the skin, the effect of each user-induced variability 
source will be isolated in this study.  
 Recent studies have demonstrated the effectiveness of RS for in vivo detection.83 
To our knowledge, previous reports include measurements made with a single 
instrument, thereby eliminating factors of instrumentation-induced variability. When 
limited to one instrument, however, multi-center studies or simultaneous data collection 
from multiple patients are impractical. Unlike other established medical tools, RS lacks 
standardized methods for system calibration, measurement, processing, data analysis, and 
reporting. Many Raman systems used in research are assembled from several vendors’ 
components, and while core components remain the same, system response may vary. 
Reports on inter-device comparison and cross-validation studies of multiple medical 
instruments are available for other optical techniques such as confocal spectral imaging, 
dual energy x-ray absorptiometry, functional magnetic resonance imaging, and 
fluorescence spectroscopy.113-117 The only report in using RS, by Rodriguez et al. 
addresses chemical analysis.118 The consistency of pharmaceutical spectra measured 
across multiple devices suggests that reliable spectral libraries can be generated from 
Raman spectra of homogeneous samples. Measurements of tissues, like the skin, pose 
more rigorous challenges for cross-validation, as the tissue characteristics may vary 
between location and time of measurement. Raman spectroscopy of the skin offers 
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diagnostic potential because it can discriminate between subtle changes in normal, 
benign, and malignant tissues. If system variation is accounted for, RS can detect these 
subtle changes in skin. Using multiple RS systems during data collection will likely add 
instrument-dependent variables. If these variables are ignored, changes in the data may be 
incorrectly attributed to the samples measured instead of the devices used. The resulting 
potential decrease in sensitivity and specificity indicate the need for standardizing RS 
systems. 
 For skin, physiological variations may exist due to age, gender, race, 
measurement location, skin type, thickness, and hydration. Any of these patient variables 
could be used to distinguish or characterize measurements. Previous in vivo Raman 
studies have demonstrated depth-dependent changes in skin composition and anatomical 
location-dependent changes in natural moisturizing factor, which is a combination of 
amino acids and salts responsible for hydrating the outermost layer of skin.61, 86 Knudsen 
et al. investigated variations in skin Raman spectra between persons, spots on the same 
body region, repeated measurements on a single spot, diurnal, day-to-day, and different 
levels of pigment.65 In these reports, however, the authors utilized either Raman 
microspectroscopy, which has different instrumentation considerations than probe-based 
techniques, or Fourier-Transform Raman Spectroscopy, which has practical limitations 
for clinical efficacy. Along with the differences between techniques, the reports do not 
consider the influence of multiple instruments. 
 The goal of this study is to examine potential sources of variability for in vivo RS 
of skin and to suggest steps for limiting the influence of confounding factors to 
standardize Raman for clinical applications. The effects of contact pressure and probe 
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angle were characterized as potential user-induced variability sources. Similarly, the 
instrumentation-induced variability was also analyzed on skin and a non-volatile 
biological analog. Physiologically-induced variations were studied on multiple tissue 
locations and patients. The effect of variability sources on spectral line shape and 
dispersion were analyzed using statistical methods. In this study, in vivo measurements 
were made on healthy human skin with four stand-alone fiber optic probe-based RS 
systems. This manuscript reports the results from this study of influential variability 
sources when comparing Raman spectral measurements. 
 
Materials and Methods 
 
Instrumentation, data processing, & statistical analysis 
 Raman spectra were acquired using RS systems with similar optical components. 
Four unique RS systems were used as described in Table II.1. Each instrument was 
controlled by a laptop computer. A custom fiber optic probe consisting of 7 collection 
fibers (300 μm), without beam-steering modifications, surrounding a central excitation 
fiber (400 μm) was used to deliver 80mW of power to the sample surface. The tissue was 
cleaned with an alcohol swab prior to the initial spectral measurement. Spectra were 
collected with a 3 second acquisition time with the room lights and computer monitor 
turned off. 
 Spectral calibration was performed for each system independently using a neon-
argon lamp with naphthalene and acetaminophen standards to correct for day to day 
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variations. A National Institute of Standards and Technology (NIST)-calibrated tungsten 
lamp was also used to account for the wavelength-dependent response of the instrument. 
The spectra were processed for fluorescence subtraction and noise smoothing using the 
modified polynomial fit and Savitzy–Golay methods, as described previously.100 
 
Table II.5. Raman Spectroscopy system components utilized for multiple system 
comparison. 
System Fiber Optic Probe Excitation Source Spectrograph Detector 
1 7x1 fiber optic 
probe 
(EmVision 
LLC, 
Loxahatchee, 
Florida) 
785nm laser  
(Process Instruments, 
Inc., Salt Lake City, 
Utah,  
PI-ECL-785-300) 
Holospec f/1.8i 
imaging 
spectrograph  
(Kaiser Optical 
systems, Ann 
Arbor, 
Michigan) 
Pixis 256BR 
CCD camera  
(Princeton 
Instruments, 
Princeton, New 
Jersey) 
2 7x1 fiber optic 
probe  
(EmVision 
LLC) 
785nm laser 
(Innovative Photonics 
Solutions (IPS), 
Monmouth Junction, 
 New Jersey, 
I0785MM0350MS) 
Acton LS 785 
imaging 
spectrograph  
(Princeton 
Instruments) 
Pixis 400BR 
CCD camera  
(Princeton 
Instruments) 
3 7x1 fiber optic 
probe  
(EmVision 
LLC) 
785nm laser (IPS, 
 I0785MU0350MS) 
Holospec f/1.8i 
imaging 
spectrograph  
(Kaiser) 
Newton DU920-
DR-BB CCD 
camera (Andor 
Technologies, 
Belfast,  
Northern 
Ireland) 
4 7x1 fiber optic 
probe  
(EmVision 
LLC) 
785nm laser (IPS, 
I0785MM0350MS) 
Holospec f/1.8i 
imaging 
spectrograph  
(Kaiser) 
Pixis 256BR 
CCD camera 
(Princeton 
Instruments) 
 
 
 Data analysis was performed on the spectral range 900-1800 cm-1, a spectral 
region rich with information from proteins, lipids, and other tissue constituents. 
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Following data processing, each spectrum was normalized to its mean spectral intensity 
across all Raman bands to account for intensity variability. This normalization method 
was chosen to ensure that all wavenumbers retained statistical independence, which is 
required for statistical analysis and is compromised when spectra are normalized to the 
intensity of a single peak. Statistical analysis was performed on the data at each relative 
wavenumber. An Analysis of Variance (ANOVA) model was used at each wavenumber 
to separate groups and calculate appropriate confidence intervals. To quantify the 
changes in spectral dispersion between groups of measurements, two metrics were 
defined: total spectral variability (𝑇𝑆𝑉 =  ∑ 𝜎𝑖𝑛𝑖=1 ), or the sum of calculated standard 
deviation (σ) at each relative wavenumber i across the entire spectrum, and total 
coefficient of variation (𝑇𝐶𝑉 =  ∑ 𝐶𝑉𝑛𝑖=1 =  ∑ 𝜎𝑖 𝜇𝑖⁄𝑛𝑖=1 ), or the sum of the coefficient of 
variation (CV) at each wavenumber where CV is the standard deviation divided by the 
mean. The TSV is an absolute measure, indicating the combined dispersion in the 
measured data. The TCV is a measure of spectral dispersion relative to the data mean. 
Samples with low variability would have TSV and TCV values approaching zero, 
indicating reproducible and consistent spectral measurements. 
 
Patients and Samples 
 Since inter-patient differences have been previously addressed by Knudsen et al., 
volunteers were of similar age and skin pigmentation with no history of skin disease; 
measurements were obtained from multiple, visibly-normal locations avoiding hair 
follicles, nevi, and other dark spots. Because skin is a potentially variable standard that 
undergoes continuous changes in hydration, a non-volatile biological analog was also 
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measured in each study to standardize spectral measurement and comparison. In this 
manuscript, generic intact vitamin E gel capsules were chosen as a homogeneous sample 
to isolate the impact of each variable, independent of tissue changes. Vitamin E gel 
capsules were chosen because they have several Raman scattering bands of varying 
intensity within the fingerprint region. Its peaks are broader than other drug formulations 
and measurements exhibit broad fluorescence signal likely due to the capsule 
composition (gelatin and glycerol). The layered composition and spectral traits of the 
capsules mimic the structure of skin and detected signals; accordingly, identical 
collection, processing, and analysis procedures were used to draw comparisons. 
 
User-induced variability 
 Contact pressure and probe angle were the user-induced sources investigated. To 
isolate the impact of probe pressure, force values were quantified while five instrument 
operators applied probe pressures at three different levels. Raw chicken breast, used as a 
skin phantom, was placed on a calibrated scale, and the force applied by each operator 
was recorded as the operator held the probe in contact with the tissue for 3 seconds. The 
contact pressure tests were repeated at arbitrarily defined low, medium, and high levels, 
as perceived by the user. For these tests, operators were instructed that low pressure 
should minimally indent the skin surface while maintaining contact for the duration of the 
simulated measurement. Similarly, high pressure should simulate firm, stable contact 
with tissue that deforms. Subsequent RS measurements were made by a single operator 
with calibrated weights attached to a fiber optic probe mounted in a uni-axial stage, as 
previously described.112 Spectra were acquired while applying different pressures at 
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levels encompassing the range of values observed during the probe operator tests. The 
effect of the angle between the tip of the probe and the tissue surface was examined by 
incorporating a rotational stage into the previous setup. Replicate measurements were 
acquired by a single operator in 2° increments up to ±10° from normal. For consistency, 
all measurements of the skin were obtained from the volar surface (palm side) of the 
forearm. 
 
Instrumentation-induced variability 
 System stability was investigated for drift between collections and measurement 
repeatability after probe replacement. For measurement repeatability across time, 
measurements were made from vitamin E and a 1 cm2 region of skin on the inner surface 
of the forearm. Measurements were made by a single operator over the course of 1-1.5 
hours at 10 minute intervals in 2 sets over the course of a single day. A uni-axial 
translation stage held the probe in gentle contact with the sample controlling for pressure 
and angle. Six time points were collected in the morning and 9 more in the afternoon. For 
probe replacement, the uni-axial translation stage was used to measure skin and vitamin E 
controlling for contact pressure and angle of incidence. Repeated collections were 
acquired with the probe in contact with the sample. Subsequent measurements were made 
after the probe was translated away from and back into contact with the sample to mimic 
a controlled replacement of the probe and limit any photobleaching effects. 
 The performance of the 4 different systems was assessed through measurements 
of both the skin and vitamin E. Measurements were made of the skin using the systems 
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listed in Table II.1. All measurements were obtained in a single room on a single 
afternoon to control for temporal or environmental effects. Contact pressure and probe 
angle were controlled, and visible superficial blood vessels were avoided during probe 
placement. 
 
Physiologically-induced variability 
 The measurements obtained with each of the 4 systems were repeated on 2 
volunteers at multiple anatomical locations. The 5 skin sites measured were: 1) crease in 
index finger, 2) base of palm, 3) inner surface of forearm, 4) outer surface of forearm, 
and 5) cheek. In addition, measurements were also made on the inner surface of the 
forearm above and adjacent to a visibly-appearing large superficial blood vessel to probe 
the effect of subsurface blood vessels on the acquired spectrum. All measurements were 
controlled for temporal and environmental variables, as well as for contact pressure, 
probe angle, and the presence of visible superficial blood vessels. The biological analog 
was measured with each RS system for reliability analysis. Data was processed as 
described above. 
 
Results 
 
User-induced variability 
 Figure II.1 illustrates the influence of low, medium, and high pressure levels on 
RS of the skin. Significant differences were found between forces applied by probe 
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operators and between pressure levels applied (p<0.0001) using a 2-way ANOVA, Figure 
II.1a. However, significant differences were not detected between low and moderate 
pressure levels. The applied pressures, which were subjectively determined by each probe 
operator, exhibit large standard deviations for each of the three levels. Raman spectra 
(n=120) were acquired from normal skin at 22 different force values spanning the 3 
pressure levels listed in Table II.2. The resulting spectra exhibit many visual similarities 
(Figure II.1b) as peak positions remained constant across test parameters, but intensities 
varied. Statistical analysis determined that fewer than 2% of wavenumbers were 
significantly different between low and medium pressures at the 95% confidence level, 
indicated by asterisks in Figure II.1b. By comparison, over 67% of wavenumbers 
significantly differed between high pressure versus medium and low pressure levels at the 
same confidence level. 
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Figure II.6. (a) Averaged forces applied by probe operators during RS collection. (b) 
Raman spectra acquired from healthy normal skin (volar forearm) during application of 
probe pressure. Stars indicate statistical difference between high pressure and other 
measures. 
 
(b) 
(a) 
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Table II.6. Contact force (mean and standard deviation) applied by multiple probe 
operators 
Low 22.3±28.6 mN 
Medium 99.2±103.9 mN 
High 457.8±425.5 mN 
 
 Randomized replicate Raman measurements (n=150) were compared at 11 
different angles on the inner surface of the forearm accounting for normal (n=50), 
counter-clockwise (n=50) and clockwise (n=50) changes in the probe angle. The 
differences in probe angle had minimal impact on the obtained spectra. Mean spectra 
from each group displayed minor changes in peak intensity. Significant differences 
between groups occurred in fewer than 5% of wavenumbers (data not shown). 
 
Instrumentation-induced variability 
 In this study, Raman spectra (n=15 for each) of vitamin E and the five anatomical 
locations on two healthy volunteers were obtained on the four different RS systems. 
Mean results from the biological analog and one location (cheek) from a single patient 
are presented for each RS system in Figure II.2 a and b, respectively. The skin spectra 
obtained were visibly similar and reproducible with minor variations in peak intensities. 
Significant differences (p<0.05) were found among systems at over 50% of the 
wavenumbers after system calibration and spectral processing, which was observed 
across all tissue locations measured. 
 To test for system stability between measurements, Raman spectra (n=15 
replicates for each) were acquired from skin and vitamin E at 15 times over the course of 
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a day. Spectral shape and intensities were reproducible and consistent with the results 
obtained from 4 different systems. However, changes in spectral intensity of the skin 
resulted in significant differences (p<0.05) for over 50% of wavenumbers after 
calibration and processing. Measurements for probe placement were compared with 
measurements after the probe was replaced at nearly the same location via the uni-axial 
translation stage. After replacement, 5% of wavenumbers significantly differed between 
the groups for skin (data not shown). 
 To confirm that the observed variations between spectra were associated with the 
skin sample, vitamin E was measured during each study protocol. For all variables 
considered, including contact pressure, angle, repeatability, probe replacement, and 
measurements made across systems, there were no systematic differences between 
vitamin E spectra. For example, as quantified in Table II.3 and depicted in Figure II.2a, 
vitamin E spectra acquired across systems after data processing were completely 
reproducible. Measurements by a single system are expected to have a low total spectral 
variability, TSV, and low total coefficient of variation, TCV. When the data collected 
from multiple systems are pooled prior to calculation, the TSV and TCV give an 
indication of the absolute and relative dispersion induced by data collection with multiple 
systems. A single system had at most a TSV of 3.7 and a TCV of 22.5 for vitamin E and 
a maximum TSV of 14.4 and TCV of 57.2 for a single skin location. The pooled data 
across all systems for vitamin E had a TSV of 11.1 and TCV of 29.4, while the pooled 
measurements on a single skin location resulted in a TSV of 45.2 and TCV of 98.2. For 
both individual system and pooled calculations, the values for a single skin location are 
higher than for vitamin E. The greater values for skin compared with vitamin E suggests 
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that detected changes are primarily the result of the sample and not the system. 
Comparison of a single system and pooled data for vitamin E suggests a high level of 
overlap in the measurements obtained by different RS systems, while more complex 
interactions are associated with the skin. 
 
 Table II.7. Quantified spectral variability for skin and biological analog for individual 
RS systems and pooled data. 
Sample System TSV (AU) TCV (AU) 
Vitamin E 
1 2.149358 16.41168 
2 2.533614 22.1533 
3 3.725334 22.5385 
4 2.501374 20.02703 
Single Skin 
Site 
1 13.19235 34.58927 
2 14.36957 57.2284 
3 11.73376 45.67666 
4 14.23391 52.98108 
Vitamin E All 11.1398 29.4302 
Skin Site All 45.20325 98.18677 
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Figure II.7. (a) Raman spectra of Vitamin E as a biological analog measured by 4 RS 
systems. Identical signals were obtained after uniform collection and processing 
algorithms used. (b) Mean Raman spectra (n=15) of one skin site measured by 4 RS 
systems. 
 
(a
(b) 
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Physiological-induced variability 
 Raman spectra (n=15) were obtained from each of 5 anatomical locations on the 
upper extremity and face from 2 healthy volunteers. Based on the results, substantial 
intra-patient differences are present between unique anatomical locations (Figure II.3a). 
Measurements made were repeatable across days and patients for each location. The 
peaks with intensity variations have previously been correlated with tissue protein and 
lipid content (1440 cm-1 and 1750 cm-1) and Amides I (1645-1680 cm-1) and III (1230-
1300 cm-1).119, 120 The spectra group together into spectral families, each having a unique 
line shape. For example, there are few variations between the spectra acquired from 
family 1, the finger and palm, but these variations are not consistent with the few 
variations between family 2, the face and both sides of the arm. As quantified in Table 
II.4, when all the data from the 5 sites across a single system are pooled, the TSV is 55.1 
and TCV is 92.8. When separated into the two families described above, the values 
decrease. Combined spectra from the arm and cheek result in a TSV of 29.7 and a TCV 
of 70.6. The finger and palm spectra have a TSV of 26.3 and a TCV of 62.0 when 
combined. When a single location was considered the values were lower still, with a 
maximum TSV of 17.6 and a TCV of 54.5. The decrease in TSV and TCV indicate 
consistent spectral families when the data is grouped. The families differ in peak 
intensities at 1440 cm-1, the presence of defined peaks at 1300cm-1 and 1750cm-1, and the 
full width at half maximum (FWHM) intensity of the Amide I band centered at 1658cm-1. 
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Figure II.8. (a) Intra-patient location based differences in Raman spectra. (b) Raman 
spectra acquired from healthy skin above and adjacent to a large superficial blood vessel. 
 
 To evaluate the effect of superficial blood vessels beneath the sampling volume of 
a normal measurement, Raman measurements (n=15) were obtained from normal tissue 
(b) 
(a) 
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directly above a visible vein and adjacent to the same vein. As Figure II.3b shows, there 
are changes in spectral signatures including notable spectral disintegration from 1200-
1300 cm-1, decreased intensity at 1440 cm-1, and a broader 1658 cm-1 peak, which are all 
reproducible for measurements above a vessel. When comparing the normal 
measurements obtained from skin over the vessel in Figure II.3b to the spectra in Figure 
II.3a, the measurements over a vessel on the forearm more strongly resemble spectral 
family from the finger than the forearm itself. Grouping spectra from above the vein with 
those from the adjacent forearm resulted in a TSV of 62.5 and TCV of 91.4, compared to 
the TSV of 50.6 and TCV of 80.1 when grouping above the vein and finger spectra, 
which has no obvious meaning. 
 
Table II.8. Quantified RS single system variability for skin sites grouped into spectral 
families and pooled data. 
Grouping TSV (AU) TCV (AU) 
All skin sites 55.09592 92.83188 
Family 1 26.3364 62.00486 
Family 2 29.72205 70.62611 
Single Skin Site 17.62649 54.46361 
 
 Representative mean spectra from multiple systems for 2 locations on a single 
patient are presented in Figure II.4. Each location retains the unique spectral signature 
measured and presented in Figure II.3a for the finger (site 1) and the cheek (site 2), but 
measurements from individual systems contribute characteristic variations to the data. 
With differences in filtering and tissue fluorescence, the spectral response calibration and 
signal processing for background removal was unequal between systems and anatomical 
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locations. Despite the systematic effects on data collection by each instrument, the data 
still group consistently into spectral families with similar line shape. 
 
 
Figure II.9. Raman spectra from 2 anatomical locations on a single patient measured on 
4 RS systems. 
 
 Figure II.5 extends the previous analysis to include multiple patients and depicts 
spectral changes associated with locations on multiple patients measured with different 
systems. The results strongly mirror those of multiple locations on a single patient, where 
strong location- specific signals are present and repeatable between patients and system 
based changes impact each measurement similarly. Measurement from a single location 
resulted in consistent spectral line shape between patients and systems. However, the 
intensity of acquired spectra differed between patients and between systems. This is most 
clearly depicted in Figure II.5 by the grouping of site 2 measurements. Also, the 
intensities for spectra from patient 1 are grouped compared to the spread of patient 2 
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spectra. This effect is most obvious at the peak intensities for 1440 cm-1 (CH2 bending) 
and 1300 cm-1 (Amide III CH stretch). 
 
 
Figure II.10. Raman spectra of 2 anatomical locations reproduced for 2 patients 
measured on 4 RS systems. 
 
 Based on the ANOVA analysis presented in Figure II.6 for the complete block 
design of measurements made from 5 locations on 2 people with 4 instruments, the intra-
patient variation (“Location”) is the most influential factor. The inter-patient differences 
in the spectra account for less than 8% of the variance from the entire dataset. This value 
was minimized by controlling for inter-patient variables prior to the study. The inter-
patient differences were insignificant compared to 28% contribution from system and 
42% from location. The interaction between inter-patient and intra-patient differences is 
consistent with the patient specific changes presented in Figure II.5. 
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Figure II.11. Percent contribution by source and interaction terms to the variance of RS 
data. The presence of the Location on Patient interaction term indicates that a location 
may take a unique intensity level for each patient measured. Non-significant interaction 
terms are combined in Other and represent less than 8% of total variance. 
 
Discussion 
 
 Previous studies have investigated the use of RS to detect changes in skin, but few 
have addressed the latent sources for variability during measurement or the potential 
issues when comparing biological measurements between systems. The initial goal of this 
study was to understand how different sources of variability impact the measured Raman 
spectra of skin. An obstacle to testing these variables in tissue is the inherent 
inconsistency and sample inhomogeneity. To avoid this innate biological variation, a 
biological analog, vitamin E, was introduced. In this paper, Raman spectra acquired from 
both normal tissue and vitamin E are evaluated for the effects of three broad categories: 
user-induced, instrumentation-induced, and physiologically-based sources of variability. 
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User-induced variability 
 As a new and increasingly-used clinical tool, RS users need to understand the 
impact of contact pressure and fiber probe angle on obtaining consistent and accurate 
results regardless of the user. Analysis in this study found no significant differences or 
increased variability introduced when user-induced factors were properly controlled. 
Even with high variability in the subjectively determined pressure exerted by different 
probe operators, demonstrated in Figure II.1a, spectra with low variability can be 
obtained. The results of applying varying pressure during spectral measurement suggest 
that a range of applied pressures are acceptable for collecting reproducible and reliable 
Raman spectra (Figure II.1b and Table II.2). Spectral change was observed only in 
measurements made under high pressure, in this case over 111kPa. Previous studies have 
shown that increasing pressure can change the interactions between light and tissue, for 
example by decreasing fluorescence and increasing optical penetration depth.21-23, 34 
Increased probe pressure will compress the tissue and more densely pack Raman active 
molecules, potentially leading to more frequent Raman scattering events. Likewise, 
increased pressure could lead to occlusion under the tip of the probe, altering perfusion 
and blood content within the sample. The acceptable range of applied pressures may 
depend on variable thickness, hydration, elasticity, or other patient, location, or age 
related changes. In general, however, the probe should minimally or reversibly displace 
the tissue surface and remain in contact during the measurement. The increased 
variability introduced by high contact pressure can be avoided if users are trained to 
operate under low pressures. These findings may also allow for better measurement 
comparison, if changes in penetration depth, perfusion, and autofluorescence are desired. 
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 By changing the angle of contact between the probe and sample, the volume of 
tissue being measured will change as the light scatters. Despite this subtle change in 
interrogated tissue, few significant spectral differences were collected between signals 
over the range of measured angles. The sampling volumes of fiber-optic probes are 
relatively large compared with tissue structures, yielding a low probability that a slight 
variation in probe angle will cause dramatic changes in the spectrum. However, because 
probe collection geometries have many designs, slight variations in probe angle may 
collect signal from a different location than intended. Probe operators should understand 
the importance of using consistent angles between measurements. 
 
Instrumentation-induced variability 
 The common practice of using a single instrument during data collection has had 
both positive and negative consequences for RS. While it has simplified data 
interpretation for researchers by removing a significant variable, it has also hindered both 
data comparison and spectral database development, which are prerequisites for 
generating reliable diagnostic algorithms. In this study, the contribution of 
instrumentation-induced variability to the acquired spectra was validated and quantified 
for several potential sources. Variability between repeated measurements for time points 
and probe placement was found to be insignificant, confirming previous reports.65 During 
Raman measurements, instrumentation-induced variability was considered a system 
dependent response. This is demonstrated in Figure II.2b, where minimal intensity 
differences between systems were detected within a single location of the skin. These 
small differences were obtained after spectral response calibration, processing, and 
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normalization, which are important steps in reducing differences between instruments. 
However, these steps alone may not be sufficient to remove the effects of multiple 
instruments and probes. Spectral response calibration accounts for only the detection arm 
of an RS system and requires system isolation for calibration, which is impractical in a 
clinical setting. Other data processing options are currently under investigation. Because 
probe-based RS systems can have variable components, calibration methods need to 
account for the specific and collective responses of the system. Several research groups, 
including ours, have proposed the use of reflective standards or other similar calibration 
techniques that account for both excitation and collection branches of the system to 
address and potentially minimize these responses. When comparing spectra from a single 
location measured by multiple systems, as presented in Figure II.2, there are no 
significant differences. However, comparing spectra from a different tissue location or 
patient (Figure II.4 and Figure II.5), these signals are complicated by other factors. 
 Isolating system dependent responses with vitamin E also generated negligible 
differences in spectra acquired by different instruments after processing. The narrow 
range of detected Raman signal for the biological analog, depicted in Figure II.2a, 
confirm the instrument stability and reliability which is needed for cross-validation and 
spectral library generation. After investigation of numerous vitamins and organic 
products, including vitamin B12, fish oil, and coffee, vitamin E was chosen as the best 
mimic for soft tissue signals. As the interrogated sample becomes more heterogeneous, 
the complex interactions of inherent scattering and system-dependent response increase 
spectral variability. This result is demonstrated in Table II.3, where the TCV for vitamin 
E of separate systems are approximately equal to the pooled value for all systems. In 
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contrast, the TCV for skin of separate systems are half the value for the data pooled for 
all systems, demonstrating that the complexity of skin results in increased variability that 
differ between RS systems. For measurements made with separate RS systems, users 
must understand the implications for cross-system comparison and determine how 
spectral changes introduced by separate instruments will influence the diagnostic 
capability of an algorithm. Using a biological analog can aid in evaluating multiple RS 
instruments for consistent measurement and comparison of tissue spectra.  
 
Physiologically-induced variability 
 Variability sources based on characteristic tissue differences between multiple 
locations on a single patient and between patients were identified as important factors for 
RS of the skin. The anatomical location analysis yielded spectra with visibly and 
statistically significant differences (Figure II.3). This result is consistent with anatomical 
knowledge of the diverse heterogeneity of skin. Multiple studies have documented the 
anatomical location-based changes in many skin properties including thickness, presence 
of hair, tissue hydration, pigmentation, sun exposure/damage, subsurface structures, and 
compositional differences of lipids and proteins.64, 121-123 Raman scattering signals from 
different anatomical locations are distinct, so tracking where such measurements are 
made is critical when comparing across locations. Separating the anatomical locations 
into distinct spectral families, based on intensity and line shape as in Table II.4, may be a 
more thorough comparison of physiologically-induced changes that are not directly 
caused by variations in the measurement location. 
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 Statistical analysis reveals that the spectral variance and primary source of 
variability depends on peak intensity. TSV is dominated by fluctuations in peak intensity 
of major Raman active bands, with 1440 cm-1 (CH2 bending) accounting for nearly 30% 
of total variability in the data and 1300 cm-1 (Amide III CH stretch) for another 10%. 
Physiologically-induced variability, due to measurement location, dominates the 
dispersion sources when comparing multiple anatomical locations for a single system and 
appears at strong Raman peaks. Instrumentation-induced variability dominates regions of 
peak shoulders and background subtraction when comparing a single measurement 
location across different systems. 
 Significant spectral differences were also observed between patients (Figure II.5). 
Studies from our lab and others have reported the sensitivity of RS to patient-based 
variables.65, 124 Some of the potential variables that may contribute to the observed inter-
patient changes in spectral signature for normal healthy skin include hormonal variations, 
BMI, gender, race/ethnicity, age, accumulated photodamage/UV exposure, and 
pigmentation. Knudsen et al. reported significant peak intensity ratio differences between 
patients, which agree with findings presented here. In that report, a single location 
(buttocks) across 13 patients yielded mean values ranging from 0.94-1.15 for the intensity 
ratio of Amide I (1660 cm-1)/CH2 bending (1440 cm-1). The mean values measured 
between patients here ranged from 0.70-0.76 for this ratio. The differences between the 
reported peak ratios are likely the result of variations in study equipment and processing 
procedures, making comparative studies between institutions difficult. However, the 
variation in values is consistent between reports, indicating inter-patient changes detected 
in the skin. Further analysis of our data suggests that these ratios are dependent upon 
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location of the measurement. The mean values obtained here range from 0.863 on the 
hand to 0.563 on the cheek of a single patient. 
 To simplify comparisons between patients, age and skin type were controlled. The 
inter-patient differences detected here demonstrate minor spectral changes when 
controlling for other variability sources. Physiological variability between locations 
within a single patient has been reported in the literature and suggests the need to account 
for anatomical site prior to comparison.61 A potential method to overcome these 
variations would utilize paired spectral measures, or the collection of adjacent and 
contralateral normal measurements for each measurement of interest. Difference spectra 
between the variable and paired normal locations would normalize a measurement to its 
inherent location-based signal, which could remove influences of intra-patient variation. 
Selection of the location for a paired measurement is critical due to the location-based 
variability in signal. A further complication is introduced by the presence of superficial 
blood vessels beneath the measurement location. The obtained spectrum from atop the 
vessel neither replicates skin measurements nor the reported spectra of blood, suggesting 
that signal changes are not derived from the blood alone.86 The results in Figure II.3b 
suggest that paired measurements should come from adjacent or contralateral locations of 
normal tissue, avoiding hair and visible superficial blood vessels. Adjacent measurements 
from the same small area of tissue were found to be reproducible, but the size of this area 
is unknown. In general, the closer the paired measurement to the original measurement 
location, the more likely a measurement will account for normal variations.  
 Statistical comparison indicated that anatomical location most significantly 
impacts collected data, followed by instrumentation-induced variability and inter-patient 
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changes (Figure II.6). These findings suggest that when patient variables are controlled 
the detected inter-patient differences exert less influence on the data than alternate 
sources. The significant interaction term (“Location on Patient”) is likely the result of 
inter-patient variation that affects intra-patient changes. Each patient will have unique 
effects on the spectra that will cause individual anatomical location to vary in intensity. 
The presence of this interaction complicates the interpretation and impact of multiple 
patients. As all other interaction terms combined have little influence, it is logical to 
conclude that the primary concerns for spectral variability will be the effects from 
anatomical location, system, and patient based differences. These patient specific 
differences may become the dominant source as a more diverse population of normal 
tissues is analyzed. This result further emphasizes the need to control for the 
measurement location. 
 Because the influence of a particular source of variation is not uniform across the 
spectrum, understanding and minimizing variability sources is important. Through 
ANOVA of spectra at each wavenumber, the relative impact of each source of variability 
can be discerned. Spectral libraries and algorithms for diagnosis or tissue classification 
need to perform independently of these confounding variability sources. Algorithms may 
need to account for the variances introduced by multiple instruments or compare spectral 
regions that are dominated by a common variability source. For example, the intensity of 
CH2 bending (1440 cm-1) is dominated by physiologically-induced variability, while the 
FWHM of the 1070 cm-1 feature, which is linked in-part to silica fiber signal, is 
dominated by instrumentation-induced variability. A ratio of these features would give 
inconsistent and instrument-dependent results. The dispersion of strong Raman active 
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bands are associated with differences in anatomical location and should be used for intra- 
and inter-patient comparison. Comparing regions of background subtraction will 
represent variations between multiple instruments.  
 The purpose of this paper is to examine different sources of variability that can 
impact in vivo RS measurements of skin and to suggest steps for limiting the influence of 
these confounding factors. Table II.5 briefly outlines the sources examined and the 
influences detected. These results indicate that, when properly used, contact pressure, 
probe angle, and probe replacement have no significant contribution to spectral variance. 
The use of multiple RS instruments will undoubtedly introduce some variation into the 
collected data, but options to limit these influences are under investigation. Despite these 
findings, thorough analysis of the potential sources of measurement error should be 
conducted with any system to understand the obtained results, ideally prior to the 
beginning of the study. We suggest that several steps be taken during the design and 
execution of in vivo RS skin measurements to address potential sources of variability. 
These steps are as a follows: 1) Standardized tissue cleaning protocols, such as cleaning 
with an alcohol swab, should be used to minimize error contribution (especially for 
measurements of the face and hands due to cosmetics and lotions); 2) Measurements with 
the probe should use low but consistent pressure during collection, keeping the probe 
approximately normal to the surface (user should be trained); 3) For normal 
measurements, a single collection per location is sufficient; 4) Paired measurements may 
provide normalization of a spectrum to the inherent signal based on anatomical location 
and person specific signals; 5) The selection of the location for a normal paired 
measurement should be carefully determined, avoiding hair follicles and major 
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superficial blood vessels. Furthermore, adjacent and contralateral normal measurements 
at a single location should be investigated for consistency. 
 
Table II.9. Variability sources investigated and determined effects. 
Variable Effect 
Contact pressure For low or medium pressure, no detected effect 
High pressure, significant effect detected 
Probe angle No detected effect 
Probe replacement No detected effect 
Instrument stability No detected effect for biological analog  
Significant effect detected between tissue measurements 
Multiple instruments No detected effect for biological analog 
Significant effect detected for biological samples 
Anatomical location Significant effect detected 
Presence of blood vessel Significant effect detected 
Inter-patient Significant effect;  
Minimized by controlling patient variables 
 
 
Conclusion 
 
 In general, these findings apply to probe-based measurements for all optical 
modalities; other collection configurations, such as confocal microspectroscopy, will 
likely contain alternate variability sources to address. Practically, normal tissues are not 
often studied, as they are not the focus of a novel diagnosis or treatment. The default 
assumption is that all normal samples are similar; however, complex interrelationships 
and differences between separate normal tissues exist. By expanding our understanding 
of normal tissues and the influence of data collection and instrumentation, the potential 
exists for more accurate and effective analyses to differentiate unique variables of 
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interest. The analytic methods for RS should consider the major sources of variance 
contribution prior to the development of classification algorithms. Thorough analysis of 
instrument response, stability, and calibration are important to standardize RS as a 
clinically viable tool. Measurements by separate instruments will likely exhibit unique 
responses. If these variations are understood and accounted for, measurements can be 
compared across systems and spectral libraries can be compiled. Here, practical 
considerations and results are presented that suggest how RS, and other probe-based 
optical techniques, can and should be used in vivo to minimize sources of variation prior 
to processing, comparison, and classification, leading to an application that can be used to 
accurately differentiate disease classes. 
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CHAPTER III 
 
FUTURE DIRECTIONS 
 
 For the first time, multiple fiber optic probe-based Raman spectroscopy (RS) 
systems have been evaluated for unique variability sources that impact in vivo 
measurement. The influence of user-, instrumentation-, and physiologically-induced 
factors were examined during measurements of normal healthy skin. Results of this study 
suggest that each of these categories include influential sources of variability that can 
impact the application of RS for in vivo measurement of the skin without proper control. 
 The influence of user-induced variables of probe angle and replacement had no 
significant effect on the acquired signal, but the application of high probe pressure 
resulted in altered spectral line shape. Instrument evaluation verified stability on a 
consistent biological analog (vitamin E), but in vivo spectra were found to differ 
significantly between measurements. Multiple systems also obtained consistent results 
between spectra of vitamin E, but influential effects were observed during in vivo 
measurements. Physiologically-induced variables for distinct anatomical locations, the 
presence of visible superficial blood vessels, and separate individuals all accounted for 
significant effects on the obtained Raman spectra in vivo. Despite these findings of 
significant effects of variability sources, further characterization and mitigation of 
relative impact is needed before RS of the skin can be successfully implemented and 
studied using multiple systems. 
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 An interesting finding of the previous work was that consistent signals were 
obtained independent of the angle between the probe and tissue surface, within a 
controlled range. Continued investigation must assess whether this is valid for all probe 
designs or if unmodified fiber optic probes behave differently from different 
configurations. The impact of photobleaching must also be evaluated for impact on 
repeated measurements. Similar effects were observed during probe replacement tests, 
but were controlled for by allowing relaxation time between measurements. A thorough 
understanding of these user-induced variables will promote in vivo RS applications. 
 A primary limitation for use of multiple RS systems is the lack of understanding 
for comparing independent instruments. This was addressed in the research presented 
above, but must be investigated in greater depth. The observed spectral contributions of 
each RS system must be characterized as either a fixed or random effect. With this 
knowledge, potential calibration transforms may be generated to allow direct comparison 
of measurements made by separate systems. Further investigation of the reflective 
standard for spectral response correction is necessary to further reduce system-dependent 
responses. The influence of fiber optic probe collection-excitation geometry must be 
investigated to see if the design significantly changes the acquired signal. Based upon the 
possible differences in collection volume and depth interrogated, probe optimization is 
important to ensure that signals are consistent between collections when other parameters 
are appropriately controlled. 
 Further investigations that focus on the impact of physiologically-induced 
changes in vivo would build upon the study presented above. The observed signal 
changes between anatomical sites should be expanded to obtain a better understanding of 
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locations with comparable spectra. The underlying explanation for the signal change 
associated with visible superficial blood vessels is also not yet apparent. Potential reasons 
could be based on the change in interrogated tissue, which has more smooth muscle, 
vascularity, and collagen in the vessel wall. Also, serum protein and other blood 
components could explain some of the spectral changes, if the signal were acquired from 
the vessel itself. The comparison of interpatient variability should also be expanded to a 
larger and more diverse population, to assess age, gender, BMI, and other factors that 
were accounted for previously. Finally the influence of photodamage and aging, both 
natural and premature, should be investigated with RS to determine if significant spectral 
changes are associated with these variables as well. 
 Despite the focus of this research on the skin as the target tissue of interest, the 
issues addressed in this research study are applicable to optical diagnosis of other tissues 
and technologies. Understanding the numerous and varied sources of variability that are 
present within a system are vital when planning and conducting research and analyzing 
and interpreting results. Because the systems used by many researcher groups are 
experimental and often assembled rather than purchased intact, investigating and cross-
validating results are necessary steps prior to the broad application to the research goals 
and target applications studied. The complexity of in vivo models and applications 
ultimately require precise control over experimental design to limit the error and improve 
accuracy and potentially, diagnostic outcomes. 
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